Full Press Release Details
Enochian BioSciences Inventor and Co-Founder
Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker
at the Innate Killer Summit
LOS ANGELES, April 5, 2022, (NASDAQ: ENOB) - Enochian
BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Serhat
Gumruk u, the Inventor and Co-Founder of the Company, delivered the concluding Plenary Lecture at the Innate Killer Summit in San
Diego, California as an invited speaker (Link to Presentation.)
Dr. Gumruk u's scientific
presentation focused on innovative clinical strategies he has designed to hyper-stimulate various components of the immune system, including
those that are part of innate killer immunity.
Data were presented on a novel approach using Natural
Killer (NK) cell and a subset of T-cells (known as Gamma Delta T-cells) derived from another person that induced control of HIV for 365
days in the blood of a person who was unable to achieve control with commonly used antiviral drugs due to resistance to them. Dr. Gumruk u
has completed an FDA pre-IND meeting and is in the process of preparing an Investigator Initiated IND. Enochian BioSciences owns the exclusive
license for the technology.
There was an update on a published case report (Link
to American Journal Case Reports) of a patient with recurrent glioblastoma treated with NK and dendritic cells (DC) derived from another
person who is now tumor-free for 29 months. In addition, Dr. Gumruk u presented new data on a patient with optic tract glioma for
seven years who was treated with NK and DC from another person. For the first time, the size of the tumor decreased, and the patient has
been in partial remission for five months. There was a substantial increase in the immune response to the cancer. Enochian BioSciences
is developing and holds the Intellectual Property for an approach that genetically modifies the DC to, potentially, induce an even stronger
immune response than was induced in those two individuals.
"Dr. Gumruk u was invited and made the concluding
speaker because of his pioneering work on novel clinical approaches, including with innate killer cells," said Dr. Ana Jewett, a
member of the Scientific Program Committee for the Summit who chaired several sessions and is a renowned tumor immunologist and cell and
gene therapy investigator at UCLA, "I am enthusiastic about my collaboration with Enochian BioSciences to advance their oncology
pipeline, starting with pancreatic cancer."
Dr. Mark Dybul, the CEO of Enochian BioSciences said, "I
believe it was fitting for the Summit organizers to recognize the brilliant scientific ideas of Dr. Gumruk u. Enochian BioSciences
looks forward to advancing as many of them as possible, potentially saving many, many lives."
Forward-Looking Statements
Statements in this press release that
are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information
and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline.
All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology
such as "believes," "plans," "expects," "aims," "intends," "potential,"
or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties,
including as set forth in Enochian BioScience's most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned
not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date hereof.
Contact: ir@enochianbio.com